NZ555571A - Alpha thymosin peptides as cancer vaccine adjuvants - Google Patents

Alpha thymosin peptides as cancer vaccine adjuvants

Info

Publication number
NZ555571A
NZ555571A NZ555571A NZ55557105A NZ555571A NZ 555571 A NZ555571 A NZ 555571A NZ 555571 A NZ555571 A NZ 555571A NZ 55557105 A NZ55557105 A NZ 55557105A NZ 555571 A NZ555571 A NZ 555571A
Authority
NZ
New Zealand
Prior art keywords
cancer
vaccine
cells
subject
tumor
Prior art date
Application number
NZ555571A
Other languages
English (en)
Inventor
Gustavo Antonio Moviglia
Alfred R Rudolph
Original Assignee
Sciclone Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sciclone Pharmaceuticals Inc filed Critical Sciclone Pharmaceuticals Inc
Publication of NZ555571A publication Critical patent/NZ555571A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NZ555571A 2004-12-06 2005-12-06 Alpha thymosin peptides as cancer vaccine adjuvants NZ555571A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63317504P 2004-12-06 2004-12-06
PCT/US2005/043985 WO2006062917A2 (en) 2004-12-06 2005-12-06 Alpha thymosin peptides as cancer vaccine adjuvants

Publications (1)

Publication Number Publication Date
NZ555571A true NZ555571A (en) 2009-02-28

Family

ID=36578462

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ555571A NZ555571A (en) 2004-12-06 2005-12-06 Alpha thymosin peptides as cancer vaccine adjuvants

Country Status (15)

Country Link
US (1) US20100092499A1 (enExample)
EP (1) EP1835931A4 (enExample)
JP (1) JP2008523067A (enExample)
KR (1) KR20070086663A (enExample)
CN (1) CN101072582B (enExample)
AU (1) AU2005314271B2 (enExample)
BR (1) BRPI0518571A2 (enExample)
CA (1) CA2588685A1 (enExample)
EA (1) EA015510B1 (enExample)
IL (1) IL183264A (enExample)
MX (1) MX2007006717A (enExample)
NO (1) NO20072705L (enExample)
NZ (1) NZ555571A (enExample)
UA (1) UA90493C2 (enExample)
WO (1) WO2006062917A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011506467A (ja) * 2007-12-14 2011-03-03 サイクローン・ファーマシューティカルズ・インコーポレイテッド 抗悪性腫瘍性熱ショックアポトーシス活性化因子（ｈｓａａ）と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法
JP2012526149A (ja) * 2009-05-08 2012-10-25 サイクローン・ファーマシューティカルズ・インコーポレイテッド ワクチン増強剤としてのαチモシンペプチド
WO2012109106A1 (en) * 2011-02-09 2012-08-16 Sciclone Pharmaceuticals, Inc. Thymosin alpha peptide for preventing, reducing the severity of, and treating infection
EP2804626B1 (en) 2012-01-20 2019-05-01 Fernando Thome Kreutz Autologous cancer cell vaccine
CN104507491A (zh) * 2012-03-08 2015-04-08 赛生制药有限公司 胸腺素α在治疗化脓性鼻窦炎中的应用
CN107148279B (zh) * 2014-10-21 2021-09-03 赛生药品股份国际有限公司 用免疫刺激剂治疗癌症
CN107281476B (zh) * 2017-04-06 2020-11-24 中国医科大学 一种抗原肽RL-佐剂CpGODN7909偶联物及其制备方法和应用
RU2645957C1 (ru) * 2017-04-10 2018-02-28 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ лечения лучевых повреждений мочевого пузыря
RU2663468C1 (ru) * 2017-09-25 2018-08-06 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ лечения местно-распространенного нерезектабельного рака поджелудочной железы

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US653758A (en) * 1900-03-20 1900-07-17 Austin Gale Hay-stacking device.
DE2604845A1 (de) 1976-02-07 1977-08-18 Knoll Ag Neue piperazinderivate
JPH0420624A (ja) * 1990-02-06 1992-01-24 Kanji Yokoe 勾配側溝施工法及び当該工法に使用する可変側溝
US6537585B1 (en) * 1999-03-26 2003-03-25 Guilford Pharmaceuticals, Inc. Methods and compositions for treating solid tumors
EP1196565A2 (en) * 1999-06-30 2002-04-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
JP2005510491A (ja) * 2001-10-26 2005-04-21 イミュノ−アールエックス， インコーポレイテッド 免疫抑制を逆転させるための免疫治療
WO2003035010A2 (en) * 2001-10-26 2003-05-01 Rhode Island Hospital Thymosin augmentation of genetic immunization
JP2005537246A (ja) 2002-06-28 2005-12-08 サイクローン・ファーマシューティカルズ・インコーポレイテッド サイマルファシンを用いて腫瘍抗原発現をアップレギュレートする方法
JP4629033B2 (ja) * 2003-03-28 2011-02-09 サイクローン・ファーマシューティカルズ・インコーポレイテッド チモシンα１によるアスペルギルス感染の治療
ES2428358T3 (es) * 2003-10-17 2013-11-07 Novo Nordisk A/S Terapia de combinación
JP2012526149A (ja) * 2009-05-08 2012-10-25 サイクローン・ファーマシューティカルズ・インコーポレイテッド ワクチン増強剤としてのαチモシンペプチド

Also Published As

Publication number Publication date
KR20070086663A (ko) 2007-08-27
EA015510B1 (ru) 2011-08-30
CN101072582A (zh) 2007-11-14
WO2006062917A3 (en) 2006-11-16
AU2005314271B2 (en) 2011-06-16
NO20072705L (no) 2007-09-05
CN101072582B (zh) 2012-06-27
UA90493C2 (ru) 2010-05-11
CA2588685A1 (en) 2006-06-15
EA200701166A1 (ru) 2008-02-28
EP1835931A2 (en) 2007-09-26
MX2007006717A (es) 2007-08-06
BRPI0518571A2 (pt) 2008-11-25
IL183264A0 (en) 2007-09-20
JP2008523067A (ja) 2008-07-03
WO2006062917A2 (en) 2006-06-15
US20100092499A1 (en) 2010-04-15
EP1835931A4 (en) 2008-12-17
IL183264A (en) 2010-12-30
AU2005314271A1 (en) 2006-06-15

Similar Documents

Publication Publication Date Title
EP1001806B1 (fr) Vesicule cellulaire denommee 'exosome', preparation et utilisation dans la stimulation d'une reponse immunitaire
US20100303868A1 (en) Ex vivo, fast and efficient process to obtain activated antigen-presenting cells that are useful for therapies against cancer and immune system-related diseases
WO2014161887A1 (en) Targeted cancer immune therapy
Fujii et al. Cancer immunotherapy using artificial adjuvant vector cells to deliver NY‐ESO‐1 antigen to dendritic cells in situ
Fu et al. Therapeutic antitumor efficacy of cancer stem cell-derived DRibble vaccine on colorectal carcinoma
AU2005314271B2 (en) Alpha thymosin peptides as cancer vaccine adjuvants
CN111298111A (zh) 一种治疗和/或预防癌症的药物和应用
Banchereau Dendritic cells: therapeutic potentials
RU2192274C2 (ru) Иммуногенная композиция на основе tlp
ZA200703528B (en) Immunotherapeutic formulations with Interleukin-2-neutralising capacity
JP2002502880A (ja) ハプテン改変化腫瘍細胞膜およびその使用
US20090060946A1 (en) Activation of antigen-specific T cells by virus/antigen-treated dendritic cells
WO2004096244A1 (en) Method of preparing tumor vaccine for the inducement of anti-tumor activity and a pharmaceutical composition containing the same
Das et al. Immunotherapeutic treatment strategies for primary brain tumors
CN103495157B (zh) 一种dc疫苗及其制备方法和应用
Dadwal et al. From past to present: The evolution of immunotherapy and its modern modalities
Wu et al. Reactivation of pre-existing T cell memory by a LADS-TT vaccine induces potent anti-tumor immunity in cervical and colon carcinoma models
CN121974977A (zh) 一组具有激活抗肿瘤免疫反应功能的免疫原性肽及其制备方法与应用
TR201811683A2 (tr) OTOLOG NK (Natural Killer) HÜCRELERİNİN OTOLOG KANSER HÜCRELERİYLE EŞ ZAMANLI KÜLTÜRE EDİLİP İMMUNİZE EDİLMESİ İLE KANSER AŞI TEDAVİSİ
HK1113374B (en) Immunotherapeutic formulations with interleukin-2-neutralising capacity

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: SCICLONE PHARMACEUTICALS, US

Free format text: OLD OWNER(S): SCICLONE PHARMACEUTICALS, INC.

ASS Change of ownership

Owner name: SCICLONE PHARMACEUTICALS, US

Free format text: OLD OWNER(S): SCICLONE PHARMACEUTICALS, INC.

PSEA Patent sealed
RENW Renewal (renewal fees accepted)
LAPS Patent lapsed